Cellebrite DI (CLBT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cellebrite DI reported a remarkable third-quarter 2024, achieving a milestone with $106.9 million in revenue, a 27% increase from the previous year driven by subscription growth. The company’s ARR rose to $370.8 million, and they showcased a strong adjusted EBITDA of $31.3 million. This robust performance has led Cellebrite to raise its 2024 revenue and adjusted EBITDA outlook, reflecting positive investor sentiment and market traction.
For further insights into CLBT stock, check out TipRanks’ Stock Analysis page.
